Overview

Efficacy and Safety of Two Doses of Liarozole vs. Placebo for the Treatment of Lamellar Ichthyosis

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
Lamellar ichthyosis is a congenital disease of the skin with a generalized scaling. The primary activity of liarozole is considered to be the inhibition of the degradation of a substance called retinoic acid, which is the principal endogenous regulator of growth and differentiation of epithelial tissues in mammals. The current study intends to evaluate the efficacy and safety in patients with lamellar ichthyosis.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Stiefel, a GSK Company
Treatments:
Liarozole